Compare Global X Lithium & Battery Tech ETF (LIT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Lithium & Battery Tech ETF vs TG Therapeutics Inc — how do they compare? Global X Lithium & Battery Tech ETF trades at $69.73 (market cap $1.45B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 5.6× Global X Lithium & Battery Tech ETF's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Global X Lithium & Battery Tech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Lithium & Battery Tech ETF for 56 Days and TG Therapeutics Inc for 16 Days on average.
| LIT | TGTX | |
|---|---|---|
Market Cap | $1.45B | $8.16B |
Volume | 89,392 | 1,735,121 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $91.62 | $59.06 |
52-Week Low | $53.92 | $26.94 |
Typical Hold Time | 56 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LIT (Global X Lithium & Battery Tech ETF) trades at $69.02, down 0.7% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages and oscillators. The ETF's recent performance reflects ongoing volatility in lithium markets, with short interest dropping 53.1% in September 2026. Recent news highlights continued growth in electric vehicle adoption and China's ambitious 30% NEV fleet target by 2030, supporting long-term battery technology demand.
The ETF presents exposure to the growing battery technology sector with strong catalysts from EV adoption and energy storage markets. However, investors face risks from lithium price volatility, Chinese export controls on critical minerals, and geopolitical trade tensions that could impact supply chains and performance.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
